[go: up one dir, main page]

NO20081001L - Derivater av karboksamid som antagonister for muskarinisk reseptor - Google Patents

Derivater av karboksamid som antagonister for muskarinisk reseptor

Info

Publication number
NO20081001L
NO20081001L NO20081001A NO20081001A NO20081001L NO 20081001 L NO20081001 L NO 20081001L NO 20081001 A NO20081001 A NO 20081001A NO 20081001 A NO20081001 A NO 20081001A NO 20081001 L NO20081001 L NO 20081001L
Authority
NO
Norway
Prior art keywords
antagonists
carboxamide
derivatives
muscarinic receptor
muscarinic
Prior art date
Application number
NO20081001A
Other languages
English (en)
Other versions
NO340975B1 (no
Inventor
Anthony Wood
Simon John Mantell
Paul Alan Glossop
Ross Sinclair Strang
Christine Anne Louise Watson
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NO20081001L publication Critical patent/NO20081001L/no
Publication of NO340975B1 publication Critical patent/NO340975B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser av formel (I), fremgangsmåter og mellomprodukter for deres fremstiling, deres anvendelse som muskariniske antagonister og farmasøytiske sammensetninger inneholdende disse.
NO20081001A 2005-09-21 2008-02-25 Derivater av karboksamid som antagonister for muskarinisk reseptor NO340975B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71947705P 2005-09-21 2005-09-21
US71946805P 2005-09-21 2005-09-21
US71946705P 2005-09-21 2005-09-21
PCT/IB2006/002727 WO2007034325A1 (en) 2005-09-21 2006-09-01 Carboxamide derivatives as muscarinic receptor antagonists

Publications (2)

Publication Number Publication Date
NO20081001L true NO20081001L (no) 2008-03-25
NO340975B1 NO340975B1 (no) 2017-07-31

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081001A NO340975B1 (no) 2005-09-21 2008-02-25 Derivater av karboksamid som antagonister for muskarinisk reseptor

Country Status (42)

Country Link
US (3) US7772223B2 (no)
EP (1) EP1928821B1 (no)
JP (1) JP4221447B1 (no)
KR (1) KR100976909B1 (no)
CN (1) CN101268046B (no)
AP (1) AP1983A (no)
AR (1) AR055171A1 (no)
AT (1) ATE420069T1 (no)
AU (1) AU2006293618B9 (no)
BR (1) BRPI0616111B8 (no)
CA (1) CA2623332C (no)
CR (2) CR9814A (no)
CU (1) CU20100115A7 (no)
CY (1) CY1108880T1 (no)
DE (1) DE602006004768D1 (no)
DK (1) DK1928821T3 (no)
DO (1) DOP2006000202A (no)
EA (1) EA013083B1 (no)
EC (1) ECSP088265A (no)
ES (1) ES2318794T3 (no)
GE (1) GEP20104880B (no)
GT (1) GT200600422A (no)
HN (1) HN2006032615A (no)
HR (1) HRP20090127T3 (no)
IL (1) IL189453A (no)
MA (1) MA29839B1 (no)
ME (1) ME01106B (no)
MX (1) MX2008002805A (no)
MY (1) MY143581A (no)
NL (1) NL2000241C2 (no)
NO (1) NO340975B1 (no)
NZ (1) NZ566023A (no)
PE (1) PE20070460A1 (no)
PL (1) PL1928821T3 (no)
PT (1) PT1928821E (no)
RS (2) RS51680B (no)
SI (1) SI1928821T1 (no)
TN (1) TNSN08137A1 (no)
TW (1) TWI322143B (no)
UY (1) UY29798A1 (no)
WO (1) WO2007034325A1 (no)
ZA (1) ZA200801432B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
EP2066626B1 (en) * 2006-09-22 2010-03-17 Pfizer Limited Azetidine derivatives as muscarinic receptor antagonists
US8263583B2 (en) 2007-03-16 2012-09-11 Pfizer Limited Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN103201244B (zh) * 2010-08-26 2015-06-17 阿尔比马尔公司 用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
EP3596046A1 (en) * 2017-03-15 2020-01-22 Mylan Laboratories Ltd. Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111601593B (zh) 2017-10-05 2022-04-15 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
CN113015721B (zh) 2018-09-19 2025-07-25 科迪华农业科技有限责任公司 毒莠定卤素类似物的制备
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
EP3990091A4 (en) * 2019-06-25 2023-07-12 Mylan Laboratories Ltd. METHODS AND INTERMEDIATES FOR THE PREPARATION OF 5-[3-(3-HYDROXYPHENOXY)AZETIDINE-1-YL]-5-METHYL-2,2-DIPHENYLHEXANAMIDE HYDROCHLORIDE SALT
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) * 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
AU733209B2 (en) * 1996-12-02 2001-05-10 Kyorin Pharmaceutical Co. Ltd. Novel n-substituted pyrrolidine derivatives and process for preparing the same
DE59611439D1 (de) * 1996-12-17 2007-09-06 Filtertek Bv Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規n−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
UA76571C2 (en) 2001-12-20 2006-08-15 Derivatives of 1-alkyl-1-azoniabicyclo [2.2.2.]octanecarbamate and use thereof as antagonists of muscarin receptor
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
BR0314353A (pt) 2002-09-17 2005-07-19 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio

Also Published As

Publication number Publication date
US7772223B2 (en) 2010-08-10
TW200745024A (en) 2007-12-16
HK1117163A1 (en) 2009-01-09
AU2006293618B2 (en) 2009-10-08
CR9814A (es) 2008-04-16
MY143581A (en) 2011-05-31
IL189453A (en) 2014-06-30
DK1928821T3 (da) 2009-03-16
CU23910B1 (no) 2013-06-29
KR100976909B1 (ko) 2010-08-18
EP1928821B1 (en) 2009-01-07
US20100029720A1 (en) 2010-02-04
MX2008002805A (es) 2008-04-07
HN2006032615A (es) 2010-10-04
EA200800540A1 (ru) 2008-08-29
JP2009508933A (ja) 2009-03-05
US8268881B2 (en) 2012-09-18
IL189453A0 (en) 2008-08-07
GEP20104880B (en) 2010-01-11
HRP20090127T3 (en) 2009-06-30
ES2318794T3 (es) 2009-05-01
ECSP088265A (es) 2008-04-28
US20070105831A1 (en) 2007-05-10
BRPI0616111B8 (pt) 2021-05-25
CA2623332A1 (en) 2007-03-29
ATE420069T1 (de) 2009-01-15
AU2006293618B9 (en) 2009-10-29
PE20070460A1 (es) 2007-05-14
RS20080119A (sr) 2009-05-06
DE602006004768D1 (de) 2009-02-26
PT1928821E (pt) 2009-03-10
TNSN08137A1 (fr) 2009-07-14
NL2000241C2 (nl) 2009-01-05
AP1983A (en) 2009-03-24
NL2000241A1 (nl) 2007-03-22
PL1928821T3 (pl) 2009-06-30
CR20130209A (es) 2013-09-19
UY29798A1 (es) 2007-04-30
CA2623332C (en) 2012-05-01
BRPI0616111A2 (pt) 2011-06-07
EP1928821A1 (en) 2008-06-11
CN101268046A (zh) 2008-09-17
WO2007034325A1 (en) 2007-03-29
MA29839B1 (fr) 2008-10-03
CY1108880T1 (el) 2014-07-02
GT200600422A (es) 2007-05-28
JP4221447B1 (ja) 2009-02-12
ZA200801432B (en) 2009-07-29
US20110251164A1 (en) 2011-10-13
EA013083B1 (ru) 2010-02-26
NZ566023A (en) 2010-02-26
RS50855B (sr) 2010-08-31
BRPI0616111B1 (pt) 2019-10-08
RS51680B (sr) 2011-10-31
TWI322143B (en) 2010-03-21
AU2006293618A1 (en) 2007-03-29
CN101268046B (zh) 2012-07-25
AR055171A1 (es) 2007-08-08
CU20100115A7 (es) 2011-10-14
ME01106B (me) 2013-03-20
SI1928821T1 (sl) 2009-04-30
US8486992B2 (en) 2013-07-16
NO340975B1 (no) 2017-07-31
DOP2006000202A (es) 2007-04-15
KR20080037103A (ko) 2008-04-29

Similar Documents

Publication Publication Date Title
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20071593L (no) Pyrimidinderivater
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20090628L (no) Pyridizinon derivativater
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
NO20066055L (no) Pyridinderivater
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20083582L (no) Pyridin-2-karboksamide derivater
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20090295L (no) Substituerte heteroarylderivater
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20071108L (no) Nye 4-benzylidenpiperidinderivater
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20082285L (no) 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
NO20080033L (no) Kinolinderivater som NK3-antagonister
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
DK1673354T3 (da) Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister
NO20080079L (no) AMPA-reseptorpotensiatorer